In this review, we also discussed the effects of innate immune cells on tumor cells since immuno-oncology drugs may exacerbate ACD possibly via the activation of CD8+ and/or CD4+ T cells and the inactivation of regulatory T cells and tolerogenic DCs. This evidence concerns the gene CD4 and granular corneal dystrophy type II.